Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Net Cash Flow (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Net Cash Flow for 6 consecutive years, with -$6.1 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 180.18% to -$6.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, up 224.02% year-over-year, with the annual reading at $4.5 million for FY2025, 224.02% up from the prior year.
  • Net Cash Flow hit -$6.1 million in Q4 2025 for Bolt Biotherapeutics, down from $8.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $89.9 million in Q1 2021 to a low of -$37.2 million in Q2 2021.
  • Historically, Net Cash Flow has averaged $309350.0 across 5 years, with a median of -$93500.0 in 2022.
  • Biggest five-year swings in Net Cash Flow: soared 487.47% in 2021 and later crashed 231.45% in 2024.
  • Year by year, Net Cash Flow stood at $3.7 million in 2021, then plummeted by 136.77% to -$1.4 million in 2022, then surged by 220.17% to $1.6 million in 2023, then plummeted by 231.45% to -$2.2 million in 2024, then plummeted by 180.18% to -$6.1 million in 2025.
  • Business Quant data shows Net Cash Flow for BOLT at -$6.1 million in Q4 2025, $8.2 million in Q3 2025, and $1.2 million in Q2 2025.